Prognostic impact of RAS-pathway mutations in patients with myelofibrosis

Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?

(2018) Rachel B. Salit et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

(2018) Paola Guglielmelli et al.   JOURNAL OF CLINICAL ONCOLOGY

RAS-mediated oncogenic signaling pathways in human malignancies

(2018) Abdul Q. Khan et al.   SEMINARS IN CANCER BIOLOGY

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

(2018) Jacob Grinfeld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib inRAS-mutant relapsed or refractory myeloid malignancies

(2016) Gautam Borthakur et al.   CANCER

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

(2015) K. P. Patel et al.   BLOOD

Clinical and molecular genetic characterization of myelofibrosis

(2015) Gabriela S. Hobbs et al.   CURRENT OPINION IN HEMATOLOGY

Regulation of RAF protein kinases in ERK signalling

(2015) Hugo Lavoie et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

(2014) Raajit Rampal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic impact ofRASmutations in patients with myelodysplastic syndrome

(2013) Aref Al-Kali et al.   AMERICAN JOURNAL OF HEMATOLOGY

NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions

(2013) J. Wang et al.   BLOOD

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase

(2013) M. Brecqueville et al.   HAEMATOLOGICA

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms

(2013) E Tenedini et al.   LEUKEMIA

Mutations and prognosis in primary myelofibrosis

(2013) A M Vannucchi et al.   LEUKEMIA

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner

(2011) J. Wang et al.   BLOOD

RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant

(2010) C. Ricci et al.   CLINICAL CANCER RESEARCH

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm

(2009) P. A. Beer et al.   BLOOD

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

(2009) F. H. Grand et al.   BLOOD

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

(2008) J. W. Tyner et al.   BLOOD

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation

(2008) J. Zhang et al.   BLOOD